Tag: DOAC reversal

Andexxa Vs 4F-PCC in ICH: An Ongoing Debate

by Carlton C.L. Watson, MD posted November 28, 2022 No Comments

BACKGROUND: Direct oral anticoagulants (DOACs) such as rivaroxaban [Xarelto] and apixaban [Eliquis] have become more prevalent in the aging population and are associated with intracranial bleeding at rates up to 4.2%. (Xian 2019) 4-Factor Prothrombin Complex Concentrates (4F-PCC), or K-Centra, …

NeurologyTrauma

Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?

by Sarah Aly, DO posted February 28, 2022 No Comments

Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli …

Hematology and OncologyNeurologyTrauma